Targeting CD47: The achievements and concerns of current studies on cancer immunotherapy

Journal of Thoracic Disease

Volumn 9, Issue 2, 2017, Pages E168-E174

  Huang, Yuting ^a   Ma, Yuchi ^b   Gao, Peng ^c   Yao, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity (ADCC); Calreticulin; CD47; Syngeneic; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CALRETICULIN; CD47 ANTIBODY; CD47 ANTIGEN; FC RECEPTOR; PROTEIN ANTIBODY; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL ASSAY; CRYSTALLIZATION; DRUG EFFICACY; DRUG TARGETING; HUMAN; INNATE IMMUNITY; MALIGNANT NEOPLASM; NONHUMAN; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT;

EID: 85014106358     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2017.02.30     Document Type: Article

References (35)

1. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010;142:699-713.
2. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012;109:6662-7.
3. Weiskopf K, Jahchan NS, Schnorr PJ, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest 2016;126:2610-20.
4. Liu X, Kwon H, Li Z, et al. Is CD47 an innate immune checkpoint for tumor evasion? J Hematol Oncol 2017;10:12.
5. Ansell S, Chen RW, Flinn IW, et al. A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood 2016;128:1812.
6. Chao MP, McKenna KM, Cha A, et al. Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies. Cancer Immunol Res 2016;4:Abstract nr PR13.
7. Sikic BI, Narayanan S, Colevas AD, et al. A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 2016;34:abstr 3019.
8. Petrova PS, Viller NN, Wong M, et al. TTI-621 (SIRPaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res 2017;23:1068-79.
9. Oldenborg PA, Gresham HD, Chen Y, et al. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 2002;99:3500-4.
10. Olsson M, Bruhns P, Frazier WA, et al. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 2005;105:3577-82.
11. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-85.
12. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286-99.
13. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009;106:14016-21.
14. Sockolosky JT, Dougan M, Ingram JR, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A 2016;113:E2646-54.
15. Weiskopf K, Ring AM, Ho CC, et al. Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013;341:88-91.
16. Zhao XW, van Beek EM, Schornagel K, et al. CD47-signal regulatory protein-a (SIRPa) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011;108:18342-7.
17. Chao MP, Tang C, Pachynski RK, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011;118:4890-901.
18. Anti-CD47 targeting therapy for the treatment of colon and pancreas cancers. Available online: https://baylor-ir.tdl.org/baylor-ir/handle/2104/9649
19. Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015;21:1209-15.
20. Kwong LS, Brown MH, Barclay AN, et al. Signal-regulatory protein a from the NOD mouse binds human CD47 with an exceptionally high affinity-implications for engraftment of human cells. Immunology 2014;143:61-7.
21. Willingham SB, Volkmer JP, Weiskopf K, et al. Reply to Soto-Pantoja et al. and Zhao et al.: Targeting CD47 on human solid tumors. Proc Natl Acad Sci U S A 2012;109:E2844-5.
22. Iwamoto C, Takenaka K, Urata S, et al. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment. Exp Hematol 2014;42:163-171.e1.
23. Strowig T, Rongvaux A, Rathinam C, et al. Transgenic expression of human signal regulatory protein alpha in Rag2-/-γc-/-mice improves engraftment of human hematopoietic cells in humanized mice. Proc Natl Acad Sci U S A 2011;108:131218-23.
24. Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014;32:364-72.
25. Stecklum M, Wulf-Goldenberg A, Brzezicha B, et al. Abstract B126: Correlation of tumor growth inhibition by check point inhibitors with PD-L1 expression in preclinical patient derived xenograft (PDX) models. Cancer Immunol Res 2016;4:Abstract nr B126.
26. Lv Z, Bian Z, Shi L, et al. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPa Facilitate Apoptotic Cell Clearance by Macrophages. J Immunol 2015;195:661-71.
27. Subramanian S, Parthasarathy R, Sen S, et al. Species-and cell type-specific interactions between CD47 and human SIRPalpha. Blood 2006;107:2548-56.
28. Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011;71:1374-84.
29. Subramanian S, Boder ET, Discher DE. Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site. J Biol Chem 2007;282:1805-18.
30. Weiskopf K, Ring AM, Guo N, et al. Direct SIRPa blockade augments macrophage responses to therapeutic anticancer antibodies. Blood 2014;124:2729.
31. Stefanidakis M, Newton G, Lee WY, et al. Endothelial CD47 interaction with SIRPgamma is required for human T-cell transendothelial migration under shear flow conditions in vitro. Blood 2008;112:1280-9.
32. Bergström SE, Bergdahl E, Sundqvist KG. A cytokine-controlled mechanism for integrated regulation of T-lymphocyte motility, adhesion and activation. Immunology 2013;140:441-55.
33. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010;2:63ra94.
34. Feng M, Chen JY, Weissman-Tsukamoto R, et al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A 2015;112:2145-50.
35. Li SS, Forslöw A, Sundqvist KG. Autocrine regulation of T cell motility by calreticulin-thrombospondin-1 interaction. J Immunol 2005;174:654-61.